Life Science News

The following issues have been halted by IIROC:

Company: Premier Health of America Inc.

TSX-Venture Symbol: PHA

All Issues: Yes

Reason: At the Request of the Company Pending News

Halt Time (ET): 4:00 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada .

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions

Cision View original content: http://www.newswire.ca/en/releases/archive/April2022/07/c0444.html

News Provided by Canada Newswire via QuoteMedia

PHA:CA
Premier Health of America

Premier Health of America


Keep reading...Show less
Premier Health Reports FY2022 Second Quarter Results

Premier Health Reports FY2022 Second Quarter Results

Premier Health of America Inc. (TSXV: PHA ) (the " Corporation "), a leading Canadian Healthtech company, announces it has filed its Condensed Interim Consolidated Financial Statements and Management Discussion and Analysis for its second quarter ended March 31, 2022.

Summary

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Premier Health of America

Premier Health Announces the Appointment of Giovanni Garay as Ontario General Manager

Premier Health of America Inc. (TSXV: PHA) (the " Corporation " or " Premier Health "), a leading Canadian Healthtech company, announces the appointment of Giovanni Garay as Ontario General Manager, effective immediately.

"We are very excited to have Giovanni join Premier Health. His hiring follows our recent acquisition in Ontario, and he will be an important member of the Corporation's senior leadership team," said Martin Legault, Chief Executive Officer. "Giovanni's experience with large organisations will benefit Premier Health as we continue to expand our footprint in the province." he added.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Premier Health Announces Grant of Options and Deferred Share Units

Premier Health Announces Grant of Options and Deferred Share Units

Premier Health of America Inc. (TSXV: PHA ) (" Premier Health " or the " Corporation ") announces the grant of 1,090,000 stock options to certain officers and employees of the Corporation. These stock options are granted in accordance with the terms of the stock option plan of the Corporation. All options fully vest on September 30, 2022, and each option entitles the holder thereof to purchase one (1) common share of the Corporation at a price of $0.80 per common share for a period of five (5) years from April 11, 2021. The Corporation also announces that it has granted an aggregate of 664,000 deferred share units (" DSUs ") to six directors of the Corporation. The DSUs are payable in common shares of the Corporation upon the holder ceasing to be a director of the Corporation.

About Premier Health

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Premier Health Completes the Previously Announced Acquisition of Canadian Health Care Agency

Premier Health Completes the Previously Announced Acquisition of Canadian Health Care Agency

Premier Health of America Inc. (TSXV: PHA ) (" Premier Health " or the " Corporation "), a leading Canadian Healthtech company, is pleased to announce that it has completed the acquisition of 100% of the outstanding shares of Umana Holdings Inc. (" Umana ") and its wholly-owned subsidiary Canadian Health Care Agency (" CHCA "), through a newly created wholly owned federally incorporated subsidiary, 13822214 Canada (" CanCo "), for a total consideration comprised between C$10.5M to C$14.5M (the " Purchase Price "), payable in cash, depending on the achievement of performance objectives (the " Transaction "), minus indebtedness, as more fully detailed below. As a result of the Transaction and a corporate reorganization, CHCA became a wholly owned subsidiary of the Corporation. The Corporation will continue the business of CHCA which consists in providing specialized nursing services.

"The acquisition of CHCA starts our expansion outside of the province of Quebec and consolidates our market position in Canada's northern regions" Said Martin Legault, CEO of Premier Health. " In addition, the Cambridge based agency provides us with a good management infrastructure in Ontario that will serve as a base to continue our expansion in this province. This is a strategy we are expecting to follow in other provinces as well."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Premier Health Enters Into Binding Agreement to Acquire Leading Ontario Agency Canadian Health Care Agency

Premier Health Enters Into Binding Agreement to Acquire Leading Ontario Agency Canadian Health Care Agency

Premier Health of America Inc. (TSXV: PHA ) (" Premier Health " or the " Corporation "), a leading Canadian Healthtech company, is pleased to announce that it has entered this day into a share purchase agreement (the " SPA ") to acquire, through a newly created wholly owned federally incorporated subsidiary, 13822214 Canada (" CanCo "), 100% of the outstanding shares of Umana Holdings Inc. (" Umana ") and its wholly-owned subsidiary Canadian Health Care Agency, (" CHCA ") for a total consideration comprised between C$10.5M to C$14.5M (the " Purchase Price "), payable in cash, depending on the achievement of performance objectives (the " Transaction "), minus indebtedness, as more fully detailed below. As a result of the Transaction and a corporate reorganization, CHCA will become a wholly owned subsidiary of the Corporation. The Corporation will continue the business of CHCA which consists in providing specialized nursing services.

"The acquisition of CHCA starts our expansion outside of the province of Quebec and consolidates our market position in Canada's northern regions" Said Martin Legault, CEO of Premier Health. " In addition, the Cambridge based agency provides us with a good management infrastructure in Ontario that will serve as a base to continue our expansion in this province. This is a strategy we are expecting to follow in other provinces as well."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic to announce financial results for its fourth quarter and full fiscal year 2022

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2022 on Thursday, May 26, 2022 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2022, which ended on Friday, April 29, 2022 .

Medtronic will host a video webcast at 7:00 a.m. CDT on Thursday , May 26, 2022, to discuss financial results for its fourth quarter and full fiscal year 2022. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

  • Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life
  • Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies
  • One-year outcomes for Navitor™ transcatheter aortic valve implantation (TAVI) system show the safety and effectiveness of this therapy and durable performance of the sealing cuff in minimizing paravalvular leak for patients with severe aortic stenosis

Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor™, the company's latest-generation transcatheter aortic valve implantation (TAVI) system. The company also showcased new data for MitraClip™ and Amplatzer™ Amulet™, two key components of the company's industry-leading structural heart portfolio.

All data were presented at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions, held in Paris from May 17-20, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Declares Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that on May 18, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on July 15, 2022, to shareholders of record as of June 15, 2022.

About Thermo Fisher Scientific

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU ® Research Posters Will Be Presented

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and disorders, today announced seven posters on behalf of XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), will be shared at Digestive Disease Week® (DDW) 2022 which is being held virtually and in-person in San Diego, Calif. from May 21-24, 2022 . The posters will be accessible on DDW's ePoster's website beginning Saturday, May 21, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range

Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17, 2022.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility

  • After FDA approval, Abbott could restart the site within two weeks; from the time of restart it would take six to eight weeks before product is available on shelves
  • Abbott will continue to import formula from FDA-registered facility in Ireland to help alleviate near-term supply shortage
  • CDC concluded its investigation with no findings of a link between Abbott formulas and infant illnesses

Abbott (NYSE: ABT) has agreed to enter into a consent decree with the U.S. Food and Drug Administration (FDA) related to its Sturgis, Mich. infant formula plant. The decree is an agreement between FDA and Abbott on the steps necessary to resume production and maintain the facility. This does not affect any other Abbott plant or operation. The decree is subject to court approval.

"Our number one priority is getting infants and families the high-quality formulas they need, and this is a major step toward re-opening our Sturgis facility so we can ease the nationwide formula shortage. We look forward to working with the FDA to quickly and safely re-open the facility," said Robert B. Ford , chairman and chief executive officer, Abbott. "We know millions of parents and caregivers depend on us and we're deeply sorry that our voluntary recall worsened the nationwide formula shortage. We will work hard to re-earn the trust that moms, dads and caregivers have placed in our formulas for more than 50 years."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×